Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of four antihypertensive medications with complementary mechanisms of action. The combination includes: - Losartan: An angiotensin II receptor blocker (ARB) that works by blocking the vasoactive properties of angiotensin II - Hydrochlorothiazide (HCTZ): A thiazide diuretic that increases sodium and water excretion - Amlodipine: A calcium channel blocker (CCB) that relaxes blood vessels - Spironolactone: An aldosterone receptor antagonist that causes the kidneys to eliminate unneeded water and sodium while reducing potassium loss This quadruple therapy would likely be used for resistant hypertension cases where blood pressure cannot be adequately controlled with fewer agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on losartan + hydrochlorothiazide + amlodipine + spironolactone.